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SUMMARY  
Regulatory   T   (Treg)   cells   expressing   Foxp3   transcripton   factor   are  
essential   for   immune   homeostasis.   They   arise   in   the   thymus   as   a  
separate  lineage  from  conventional  CD4+Foxp3-­  T  (Tconv)  cells.  Here,  we  
show   that   the   thymic   development   of   Treg   cells   depends   on   the  
expression  of   their  endogenous  cognate  self-­antigen.  The   formation  of  
these  cells  was   impaired   in  mice   lacking   this  self-­antigen,  while  Tconv  
cell   development   was   not   negatively   affected.   Thymus-­derived   Treg  
cells   were   selected   by   self-­antigens   in   a   specific   manner,   while  
autoreactive  Tconv  cells  were  produced  through  degenerate  recognition  
of   distinct   antigens.   These   distinct   modes   of   development   were  
associated   with   the   expression   of   T   cell   receptor   of   higher   functional  
avidity   for   self-­antigen   by   Treg   cells   than   Tconv   cells,   a   difference  
subsequently   essential   for   the   control   of   autoimmunity.   Our   study  
documents   how   self-­antigens   define   the   repertoire   of   thymus-­derived  
Treg   cells   to   subsequently   endow   this   cell   type   with   the   capacity   to  
undermine  autoimmune  attack.    
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INTRODUCTION  
CD4+  T  regulatory  (Treg)  cells  expressing  the  transcription  factor  Foxp3  play  
an  essential   role   in   immune  homeostasis.  Humans  bearing  null-­mutations   in  
the   FOXP3   gene   display   a   deficit   in   Treg   cells,   and   develop   the   fatal  
immunodysregulation   polyendocrinopathy   enteropathy   X-­linked   syndrome  
(IPEX)   early   in   childhood   (Bennett   et   al.,   2001).   Similarly,   deficiency   in   the  
Foxp3   gene   in   mice   results   in   a   lack   of   Treg   cells,   and   lethal  
immunopathology  (Fontenot  et  al.,  2003).    
  
The  inhibition  of  immunity  by  Treg  cells  necessitates  their  activation  via  
the  T  cell  receptor  (TCR)  (Levine  et  al.,  2014).  The  antigens  stimulating  Treg  
cell   activation   at   steady   state   must   be   self-­antigens   because   Treg   cells  
restrain  immune-­mediated  pathogenesis  also  in  germ-­free  mice  (Chinen  et  al.,  
2010).    
  
The   antigen   recognition   properties   of   Treg   cells   are   largely   defined  
during  their  development  in  the  thymus  (Hsieh  et  al.,  2006;;  Pacholczyk  et  al.,  
2006).   Experiments   performed  with  Nur77-­eGFP   reporter  mice   indicate   that  
Treg   cells   received   stronger   TCR   signals   than   CD4+Foxp3-­   conventional   T  
cells   (Tconv)   during   their   thymic   development   (Moran   et   al.,   2011).  
Accordingly,  a  study  using  “TCR-­cognate  antigen”  double-­transgenic  mice  has  
shown  that  a  TCR  with  high  affinity   for   the  selecting  antigen  drives  Treg  cell  
development,  while  TCRs  of  low  affinity  do  not  (Jordan  et  al.,  2001).  A  role  for  
strong  TCR  signalling  during  early  Treg  cell  specification  might  be  to  promote  
the   expression   of   TNF   receptor   super-­family   members   GITR,   OX40,   and  
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TNFR2,   which   facilitate   Treg   cell   formation   (Mahmud   et   al.,   2014),   and   to  
stimulate   the   epigenetic   changes   of   the   Foxp3,   Ctla4,   Il2ra,   and   Itgal   loci  
associated  with  Treg  cells  (Morikawa  and  Sakaguchi,  2014).    
  
The  nature  of  the  cognate  antigens  governing  Treg  cell  selection  in  the  
thymus   remains   controversial.   None   of   the   studies   mentioned   above   has  
addressed  this  issue  as  they  were  either  performed  using  artificial  transgenic  
antigens  (Jordan  et  al.,  2001)  or  only  have  provided  indication  on  the  intensity  
of  the  TCR  signalling  associated  with  Treg  cell  formation  in  response  to  non-­
defined   epitopes   (Moran   et   al.,   2011).   Although   self-­antigens   are   regularly  
evoked  as  mediators   of   this   process,   no   self-­antigen   that   selects  Treg   cells  
has  been  identified.  Moreover,  this  concept  has  been  repeatedly  questioned,  
and  some  investigators  claim  that  microbiota  has  been  the  primary  source  of  
antigens  mediating  Treg  cell  selection   (van  Santen  et  al.,  2004),(Pennington  
et  al.,  2006),    (Pacholczyk  et  al.,  2007).    
  
Here,  we  sought  to  investigate  the  identity  of  the  antigens  implicated  in  
thymic   Treg   cell   selection.   We   focused   on   Treg   cells   specific   for   myelin  
oligodendrocyte  glycoprotein  (MOG),  a  minor  component  of  the  myelin  sheath  
that   is   an   important   target   in   autoimmune   diseases   of   the   central   nervous  
system   (CNS).   Upon   activation,   CD4+   T   cells   reacting   against   MOG   can  
provoke   an   inflammatory   demyelinating   disease   of   the   CNS   in  mice,   called  
experimental  autoimmune  encephalomyelitis  (EAE),  which  is  the  primary  pre-­
clinical  model   for  multiple   sclerosis   (Fillatreau   et   al.,   2002).   In   this   disease,  
MOG-­reactive  Treg  cells  provide  an  essential  mechanism  of  protection   from  
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immune-­mediated   pathogenesis   (McGeachy   et   al.,   2005).   We   demonstrate  
that   endogenous   MOG   expression   contributed   significantly   to   the   thymic  
development   of   MOG-­reactive   Treg   cells.   We   also   have   shown   that   these  
Treg  cells  expressed  TCRs  of  higher   functional  avidity   for  MOG   than  Tconv  
cells,   and   reveal   the   importance   of   this   difference   for   the   regulation   of  
autoimmunity.    
  
	   6	  
RESULTS  
A  TCRβ  transgenic  mouse  to  study  MOG-­reactive  Tconv  and  Treg  cells    
Autoreactive  Tconv  cells  differ  in  their  capacity  to  cause  autoimmune  disease.  
Those   expressing   public   TCR   clonotypes   are   prominent   drivers   of  
pathogenesis  (van  den  Elzen  et  al.,  2004).  In  order  to  analyse  such  cells,  we  
generated   a   transgenic   mouse   (named   Kaa   mouse)   expressing   the   public  
TCRβ   clonotype   of   the   MOG-­reactive   CD4+   T   cell   response   during   EAE   in  
C57BL/6   mice   (Fazilleau   et   al.,   2006).   This   public   TCRβ   chain   contains   a  
Vβ8.2  segment  (Figure  S1A),  which  is  expressed  in  both  Tconv  and  Treg  cells  
in  the  central  nervous  system  (CNS)  of  C57BL/6  mice  with  EAE  (Figure  S1B).    
  
Naïve   Kaa   mice   contained   an   increased   frequency   of   MOG-­reactive  
Tconv  cells,  estimated  at  around  1.8%  in  spleen  using  CD40L  expression  as  
an   indicator   of   TCR   stimulation   (Figure   S1C)   (Frentsch   et   al.,   2005).   Kaa  
Tconv  cells  were  encephalitogenic  because  cells   isolated   from   lymph  nodes  
(LN)  of  Kaa  mice  immunized  with  MOG(35-­55)  expressed  interferon-­γ  (IFN-­γ)  
as  well  as   tumor  necrosis   factor-­α   (TNF-­α)   upon  ex  vivo   re-­stimulation,  and  
induced  EAE  in  recipient  mice  upon  adoptive  transfer  (Figure  1A).  Tconv  cells  
from  naïve  Kaa  mice  stimulated  under  the  same  condition  also  induced  EAE  
in  recipient  mice,  while  non-­transgenic  Tconv  cells  had  no  effect  (Figure  1B).   
  
Despite  harbouring  encephalitogenic  Tconv  cells,  Kaa  mice  developed  
a   milder   EAE   than   wild-­type   mice   upon   immunization   with   MOG(35-­55)  
(Figure   1C).   We   hypothesized   that   the   Kaa   mouse   contained   elevated  
numbers   of   MOG-­reactive   Treg   cells.   Using   MOG-­I-­Ab   tetramers   we   found  
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that   7.2   %   of   Treg   cells   were   MOG-­reactive   in   the   LN   of  
Kaa.Foxp3.IRES.eGFP   mice   (Figure   1D).   These   Treg   cells   were   functional  
since   the   proliferation   of   Kaa   T   cells   stimulated   with   MOG(35-­55)   was  
increased  after  Treg  cell  depletion  (Figure  1E),  and  adoptive   transfer  of  Kaa  
Treg  cells  improved  the  course  of  EAE  in  recipient  C57BL/6  mice,  while  non-­
transgenic   Treg   cells   had   no   effect   (Figure   1F).   This   protection   was  
associated   with   an   accumulation   and   proliferation   of   adoptively   transferred  
Kaa  Treg  cells  in  the  draining  LN  of  recipient  mice  immunized  with  MOG(35-­
55),   which   was   not   observed   in   control   groups   (Figure   1G   and   S1D).  
Moreover,   interfering   with   Treg   cell   function   in   Kaa   mice   exacerbated   EAE  
(Figure   1H).   Collectively,   these   data   demonstrate   that   Kaa   mice   contain  
protective  MOG-­reactive  Treg  cells  that  efficiently  counteract  encephalitogenic  
MOG-­reactive  Tconv  cells.    
  
Treg  and  Tconv  cells  differently  recognize  MOG  in  the  Kaa  mouse  
Treg   and   Tconv   cells   express   distinct   TCR   repertoires   in   wild-­type   mice  
(Hsieh  et  al.,  2006;;  Pacholczyk  et  al.,  2006),  suggesting  that  they  differ  in  their  
antigen   recognition   properties.  We   sought   to   address   whether   this   was   the  
case  for  cells  specific  for  a  disease-­relevant  autoantigen.    
  
To  characterize  the  TCRα  chains  expressed  by  disease-­relevant  MOG-­
reactive   Treg   and   Tconv   cells,   we   induced   EAE   in   Kaa   mice   on   a  
Foxp3.IRES.eGFP.Tcra+/-­Tcrb+/-­   background,   and   isolated   CD4+GFP+   cells  
(Treg   cells)   as  well   as  CD4+GFP-­   cells   (Tconv   cells)   from   their   CNS   at   the  
peak  of  disease.  TCRα  sequences  were  amplified  from  these  cells  using  a  5’  
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RACE   PCR   to   allow   unbiased   repertoire   analysis.   Three   independent  
experiments   were   performed,   yielding   a   total   of   3592   and   3928   TCRα  
sequences,  which  corresponded  to  1011  and  1086  unique  TCRα  sequences  
for   Treg   and   Tconv   cells,   respectively.   We   focused   our   analyses   on  
sequences   found   in   each   of   the   three   samplings   for   Treg   or   Tconv   cells,  
assuming  that   these  would  derive   from  disease-­relevant  MOG-­reactive  cells.  
This  yielded  21  and  22  TCRα   for  Tconv  and  Treg  cells,   respectively   (Figure  
S2A),   corresponding   to   40   distinct   TCRα   (three   sequences  were   present   in  
both   subsets).   Importantly,   the   frequency   of   these   TCRα   among   the   total  
number   of   sequences   analysed   for   each   experiment   confirmed   their   biased  
representation  in  the  Treg  or  Tconv  cell  compartments  (Figure  2A).    
  
We  could  re-­express  30  of  these  40  TCRα    (Figure  S2B  and  Table  S1)  
together   with   the   Kaa   TCRβ   in   a   TCR-­deficient   cell   line   that   produced   IL-­2  
proportionally   to   the   strength   of   stimulation   of   the   ectopic   TCR   (Letourneur  
and  Malissen,   1989).   The  majority   of   the   TCRs   tested   (28/30)   were   MOG-­
reactive  (Figure  S2B).  The  TCRs  from  Treg  cells  (n=17)  conferred  the  cell  line  
a  markedly  stronger  reactivity  towards  MOG  than  did  Tconv  cell-­derived  TCRs  
(n=11)   (Figure   2B).   The   bi-­modal   distribution   of   this   response   showed   that  
TCRs   of   Treg   and   Tconv   cells   belonged   to   two   distinct   classes   differing   by  
their  functional  avidity  for  MOG.    
  
To   assess   if   this   difference   in   functional   avidity   was   associated   with  
qualitative  differences  in  the  recognition  of  the  antigen,  we  evaluated  whether  
distinct   residues   within   MOG(35-­55)   were   important   for   stimulating   Treg  
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versus   Tconv   cell   TCRs.   First,   we   activated   a   sample   of   the   cell   lines  
expressing  TCRs  from  Treg  (n=7)  or  Tconv  (n=6)  cells  with  modified  MOG(35-­
55)   peptides   containing   alanine   substitutions   at   each   of   the   21   amino   acid  
positions,  and  quantified  their  IL-­2  production  relative  to  the  response  elicited  
by   the   original   MOG(35-­55)   peptide   (Figure   S2C).   Based   on   the   obtained  
results,   we   then   focused   on   six   altered   peptides   that   affected   the   cell   lines  
expressing   TCRs   from   Treg   and   Tconv   cells   in   a   distinct   manner   (Figure  
S2C),  and   re-­tested   them  on   the  28  cell   lines  available   (Figure  2C).  Five  of  
these  peptides  elicited  distinct  IL-­2  responses  depending  on  the  origin  of  the  
TCR  expressed  by  the  cell  lines.  In  particular,  the  49(HàA)  peptide  increased  
the   amount   of   IL-­2   produced   by   cell   lines   expressing   Tconv   cell   TCRs   by  
about  10-­fold  while  having   little  effect  on   the   response  of  cells  bearing  Treg  
cell   TCRs.   From   these   results,   we   conclude   that   the   TCRs   from   Treg   and  
Tconv  cells  characterized  in  this  study  differently  recognize  the  MOG  antigen  
with  conserved  properties  within  each  class.    
  
A  limitation  of  the  clonal  analyses  described  above  is  that  they  are  only  
feasible   for   a   limited   number   of   TCRs.   In   an   attempt   to   generalize   these  
findings,  we   tested   the  prediction   that   the  49(HàA)  peptide  should  be  more  
encephalitogenic   than   the   original   self-­antigen   because   it   was   a   stronger  
Tconv   cell   stimulant.   Indeed,   the   variant   49(HàA)   induced   a   more   severe  
EAE   than   the   original  MOG(35-­55)   peptide   (Figure   2D),   correlating  with   the  
induction   of   stronger   encephalitogenic   CD4+   T   cell   responses   (Figure   2E).  
These   results   corroborate   the   notion   that   Tconv   and   Treg   cells   carry   TCRs  
with  different  antigen  recognition  properties.    
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The  TCR  instructs  the  development  of  MOG-­reactive  Treg  cells    
We   evaluated   the   capacities   of   TCRs   cloned   from  MOG-­reactive   Treg   and  
Tconv  cells  to  drive  Treg  cell  development   in  vivo  generating  TCR  retrogenic  
mice  using  six  TCRs  from  Treg  cells  and  six  TCRs  from  Tconv  cells.    
  
Donor-­derived  CD4+   T   cells   were   detected   in   the   blood   of   retrogenic  
mice  starting  two  weeks  after  reconstitution,  and  followed  distinct  patterns  of  
repopulation  depending  on  the  origin  of   the  TCR.  Donor-­derived  CD4+  T  cell  
numbers   were   lower   (Figure   3A),   while   Treg   cell   frequencies   were   higher  
(Figure  3B)   in  mice  prepared  with  TCRs   from  Treg  cells   compared   to   those  
produced  with  TCRs   from  Tconv  cells.  Similar  differences  were  observed   in  
thymus  and  spleen  (Figure  3C),  as  well  as  LN  (Figure  S3A),  both  in  frequency  
and  absolute  number  of  Treg  cells.  Thus,  TCRs  from  MOG-­reactive  Treg  cells  
generated  Treg  cells  more  efficiently  than  TCRs  from  Tconv  cells.  In  line  with  
previous   studies,   however,   none  of   the  TCRs   induced   the   formation  of   only  
Treg  cells  (Bautista  et  al.,  2009;;  Leung  et  al.,  2009).    
  
We   then  measured   the   expression   of  Helios,   a   transcription   factor   of  
the   Ikaros   family   described   as   a   marker   of   thymus-­derived   Treg   cells  
(Thornton  et  al.,  2010).  Nearly  all  donor-­derived  Treg  cells  expressed  Helios  
in  mice  made  with  Treg  cell  TCR,  while  fewer  Treg  cells  expressed  Helios  in  
mice  generated  with  TCRs  from  Tconv  cells  (Figure  3D).  As  expected,  Tconv  
cells   did   not   express   Helios   (Figure   S3B).   Further   cytometric   analyses  
indicated   that   donor-­derived   Treg   cells   were   mostly   CD25+CD62L+GITRhigh  
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irrespective  of   the  origin  of   their  TCRs,  while  Tconv  cells  displayed  different  
phenotypes  (Figure  S3C).    
  
Taken   together,   our   results   show   that  TCRs  of  high   functional  avidity  
for  MOG  have  a  superior  capacity  to  generate  Helios-­expressing  Treg  cells.    
  
Endogenously   expressed   MOG   controls   the   development   of   MOG-­
reactive  Treg  cells    
The   role   of   self-­antigens   in   Treg   cell   development   remains   controversial.  
Here,   we   examined  whether  MOG  was   required   for   the   formation   of  MOG-­
reactive  Treg  cells  using  Mog-­/-­  mice  (Hovelmeyer  et  al.,  2005).    
  
We   selected   four   Treg   cell-­derived   TCRs   to   prepare   retrogenic  mice  
using   wild-­type   and   Mog-­/-­   mice   as   recipients.   Absolute   numbers   and  
frequencies  of  Treg  cells  among  donor-­derived  CD4+  T  cells  were  reduced  in  
the   thymus   of   Mog-­/-­   mice   compared   to   controls   (Figure   4A).   Similar  
differences  were  observed  in  spleens  and  LN,  although  they  were  less  striking  
for   some   TCRs   (Figure   4B   and   S4A).   Fewer   donor-­derived   Treg   cells  
expressed   Helios   in   Mog-­/-­   mice,   compared   to   controls,   illustrating   the  
contribution  of  MOG   to   the  normal  development  of  MOG-­reactive  Treg  cells  
(Figure  4C  and  S4B).  Expression  of  CD25,  CD62L,  or  GITR  was   in  contrast  
not  influenced  by  MOG  (Figure  S4C-­E).    
  
To   address   how   endogenous   MOG   expression   influenced   the  
development   of   MOG-­reactive   Treg   cells   in   a   polyclonal   setting,   we  
	   12	  
reconstituted   wild-­type   and   Mog-­/-­   mice   with   bone   marrow   cells   from  
Kaa.Foxp3.IRES.eGFP  mice,  and  used  MOG-­I-­Ab  tetramer  to  quantify  MOG-­
reactive   Treg   and   Tconv   cells   (Figure   4D).   The   frequency   of   MOG-­I-­Ab-­
binding  cells  among  CD4+GFP+  Treg  cells,  and  the  absolute  number  of  MOG-­
I-­Ab-­binding  CD4+GFP+  Treg  cells  were  markedly   reduced   (absolute  number  
reduced  by  42%)   in   the   thymus  of  Mog-­/-­  mice  compared   to  controls   (Figure  
4D).  These  results  show  that  the  absence  of  a  single  self-­antigen,  here  MOG,  
is  sufficient  to  reduce  the  formation  of  MOG-­reactive  Treg  cells.    
  
In   contrast,  MOG-­reactive  Tconv   cells  were  efficiently   selected   in   the  
absence  of  MOG.  They  were  present  in  similar  numbers  in  wild-­type  and  Mog-­
/-­  retrogenic  mice  (Figure  S4F),  and  were  more  abundant  in  the  thymus  of  the  
chimera   mice   bearing   a   polyclonal   repertoire   that   lacked   MOG   expression  
compared  to  controls  (Figure  4E).  Thus,  distinct  cognate  antigens  control  the  
formation  of  MOG-­reactive  Treg  and  Tconv  cells  in  the  thymus.    
     
TCR   functional   avidity   controls   the   activity   of   Treg   and   Tconv   cells  
during  autoimmune  disease    
We   next   addressed   whether   the   function   of   Treg   and   Tconv   cells   in   the  
periphery   was   influenced   by   the   functional   avidity   of   their   TCRs   for   the  
disease-­relevant  self-­antigen.  
  
   First,   we   ectopically   expressed   two   MOG-­reactive   TCRs   from   Treg  
cells  and  two  MOG-­reactive  TCRs  from  Tconv  cells  in  polyclonal  Tconv  cells  
through  TCR  gene   transfer   (Figure  5A).  Although   the   four  T  cell  populations  
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displayed  similar   IFN-­γ  production  upon  stimulation  with  PMA  and  ionomycin  
(Figure  S5A),   those  expressing  a  TCR  from  Treg  cells  produced  more   IFN-­γ  
upon  stimulation  with  MOG(35-­55)  (Figure  5B).  Upon  adoptive  transfer,  these  
four   Tconv   cell   populations   expanded   comparably   in   recipient   mice   (Figure  
5C).  However,  Tconv  cells  expressing  a  TCR  from  Treg  cells  caused  a  more  
severe  EAE  in  recipient  mice  with  an  earlier  disease  onset  (Figure  5D)  and  a  
higher  cumulative  disease  burden  (Figure  S5B).  Thus,  the  functional  avidity  of  
their  TCR  for  MOG  determines  the  encephalitogenic  potential  of  Tconv  cells.    
  
   We  next  ectopically  expressed  the  same  four  TCRs  in  polyclonal  Treg  
cells   (Figure   5E).   Upon   activation   with   MOG(35-­55),   such   engineered   Treg  
cells  suppressed  responder  T  cell  proliferation  in  a  dose-­dependent  manner  in  
vitro   (Figure   S5C).   Upon   adoptive   transfer,   Treg   cells   expressing   a   TCR   of  
high   avidity   for   MOG   afforded   better   protection   from   EAE   than   Treg   cells  
carrying  a   low  avidity  TCR   (Figure  5F  and  S5D),   correlating  with  a  stronger  
reduction   of   the   autoreactive   T   cell   response   in   recipient  mice   (Figure   5G).  
We  conclude  that  the  functional  avidity  of  their  TCRs  for  MOG  determines  the  
protective  function  of  Treg  cells  in  EAE.    
  
Engineered   Treg   cells   have   therapeutic   function   when   administered  
after  EAE  induction  
We  next   characterized   how  polyclonal   Treg   cells   expressing   a   TCR  of   high  
functional  avidity  for  MOG  protected  recipient  mice  from  EAE  in  a  prophylactic  
setting,  and  determined  whether   these  Treg  cells  were  also  beneficial  when  
adoptively  transferred  after,  or  long  before,  EAE  induction.    
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In   a   prophylactic   setting   the   protection   afforded   by   engineered   Treg  
cells   was   associated   with   their   accumulation   (Figure   S6A),   and   a   reduced  
encephalitogenic  T   cell   response   (Figure  6A)   in   the  draining  LN  of   recipient  
mice.  The   transferred  Treg  cells  also  migrated   to   the  CNS  of   recipient  mice  
(Figure  S6B),  correlating  with  a  decreased  inflammatory  immune  cell  infiltrate  
(Figure   6B   and   S6C).   Thus,   the   engineered   Treg   cells   suppressed   the  
pathogenic  reaction  in  both  secondary  lymphoid  organs  and  the  target  tissue.  
Transduced   Treg   cells   still   reduced   disease   severity   when   administered   in  
recipient  mice  at  EAE  onset  (Figure  6C).  They  also  persisted  long-­term  after  
transfer   in   naïve   recipient   mice   (Figure   S6D),   and   when   these   mice   were  
immunized   six   weeks   after   Treg   cell   transfer,   the   latter   cells   reduced   the  
activation  of  the  pathogenic  T  cell  response  (Figure  S6E),  the  progression  of  
EAE  course  (Figure  6D),  and  disease-­associated  mortality   (Figure  S6F).  We  
conclude   that   polyclonal   Treg   cells   engineered   to   express   a   TCR   of   high  
functional   avidity   for   a   disease-­relevant   antigen   might   provide   a   cellular  
therapy  to  treat  diseases  caused  by  unwanted  T  cell  responses.    
  
CTLA-­4   expression   is   essential   for   the   suppressive   function   of   Treg  
cells  engineered  with  TCRs  of  high  functional  avidity  
We  next  asked  whether  polyclonal  Treg  cells  activated  ex  vivo  and  genetically  
engineered   to   express   a   TCR   of   high   functional   avidity   for   MOG   remained  
reliant  on  mechanisms  commonly  used  by  Treg  cells  to  suppress  immunity.    
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CTLA-­4   is   pivotal   for   Treg   cell-­mediated   suppression   (Wing   et   al.,  
2008),  even  though  one  study  found  that  it  was  dispensable  for  the  limitation  
of  CNS  autoimmunity  (Verhagen  et  al.,  2009).  To  produce  MOG-­reactive  Treg  
cells   having   reduced   amounts   of   CTLA-­4   we   developed   a   retroviral   vector  
containing  the  MOG-­reactive  TCR  cassette  and  two  miRNAs  to  silence  CTLA-­
4   (Figure  7A).  The  silencing  of  CTLA-­4   (Figure  7B)  abolished   the  protection  
afforded  by  MOG-­reactive  Treg  cells   (Figure  7C).  These  Treg  cells   retained  
low  CTLA-­4  amounts   in   recipient  mice   (Figure  7D),  and  expanded   less   than  
control  MOG-­reactive  Treg  cells  (Figure  7E).  Thus,  CTLA-­4  is  essential  for  the  
therapeutic  effect  of  engineered  Treg  cells  against  EAE.  In  contrast,  silencing  
of  CD49d  or  GITR   (Figure   7B)   did   not   impair   the   protective   effect   of  MOG-­
reactive   Treg   cells   (Figure   7C).   It   is   remarkable   that   CD49d   seemed  
dispensable   for   the   protective   function   of   adoptively   transferred   Treg   cells,  
because  this   integrin   is  essential   for   the   infiltration  of  pathogenic  T  cells   into  
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DISCUSSION    
The   antigens   selecting   thymus-­derived   Treg   cells   remain   poorly   defined.  
Here,   we   reported   the   identification   of   a   natural   self-­antigen   controlling   the  
generation  of  thymus-­derived  Treg  cells.  Moreover,  we  have  documented  how  
differences   in   the   properties   of   the  TCR   instructing  Treg   cells   development,  
compared   to   those   producing   Tconv   cells,   contribute   to   limit   the   risk   of  
autoimmunity.    
  
   It  is  noteworthy  that  the  absence  of  a  single  antigen,  MOG,  resulted  in  
a   marked   loss   of   MOG-­reactive   Treg   cells   in   the   thymus   because   it   is  
generally   admitted   that   TCR   recognition   of   antigen   is   degenerated   (Mason,  
1998;;  Vrisekoop  et  al.,  2014).  Degenerate  antigen  recognition  by  TCRs  is  an  
essential   feature   of   T   cell   development   since   T   cell   progenitors   are   first  
positively   selected   on   self-­antigens   in   the   thymus   before   they   give   rise   to  
mature  Tconv  cells  that  can  then  during  infection  react  towards  unrelated  non-­
self   antigens   in   the   periphery.   The   degeneracy   of   T   cell   recognition   is   also  
important  during  heterologous  immunity  (Welsh  and  Selin,  2002).  Such  a  high  
amount  of  degeneracy  has  been  proposed  to  be  essential  for  limiting  possible  
holes   in   the  TCR  repertoire  and  to  ensure   the  robustness  of  T  cell   immunity  
(Anderton   and  Wraith,   2002;;   Mason,   1998;;   Sewell,   2012;;   Vrisekoop   et   al.,  
2014).   A   drawback   of   degeneracy   is   however   the   potential   recognition   of  
autoantigens,   and   consequently   the   risk   of   autoimmunity   (Skowera   et   al.,  
2008;;  Wooldridge  et  al.,  2012).  In  contrast,  our  data  obtained  with  retrogenic  
mice   highlighted   that   for   some  MOG-­reactive   TCR,   the   expression   of  MOG  
was   critical   for   the   development   of   Treg   cells.   In   this   case   the   selecting  
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peptide  can  also  act  as  an  agonist  to  stimulate  the  activation  of  MOG-­reactive  
Treg   cells   in   the   periphery.   Thus,   some   Treg   cells   might   follow   the   central  
dogma   of   the   clonal   selection   theory,   which   proposes   that   an   individual  
lymphocyte   is  specific   for  a  single  antigen  (Jerne,  1955,  1971).   It   is  possible  
that  antigen  recognition  by  Treg  cells  is  less  degenerate  than  for  Tconv  cells,  
and   that   the  resulting  holes   in   the  regulatory  repertoire  are  required   to  allow  
efficient   immunity   against   non-­self   antigens.  Our   data   indicate   however   that  
this  mode   of   Treg   cell   development   is   not   absolute.   First,   Tconv   cell   TCRs  
allowed   the  development  of   low  numbers  of  Treg  cells.  Although   these  cells  
might   provide   little   protection   from   CNS   autoimmunity   due   to   the   low  
functional  avidity  of   their  TCRs  for  MOG,  they  might  recognize  some  foreign  
antigens   with   high   affinity,   which   could   explain   the   detection   of   Treg   cells  
reacting  against  microbial  antigens  in  the  naïve  peripheral  repertoire  (Moon  et  
al.,   2011).  Second,   some  of   the   four  TCRs   cloned   from  MOG-­reactive  Treg  
cells  generated   low  amounts  of  Treg  cells   in   the   thymus  of  Mog-­/-­   retrogenic  
mice.   Thus,   in   addition   to   the   pathway   of   Treg   cell   development   driven   by  
endogenous  antigen  presentation  in  the  thymus,  other  processes  contribute  in  
parallel   to   the  generation  of   the  peripheral  Treg  cell  pool.  This  might  explain  
why   in   a   polyclonal   repertoire   deficiency   in  MOG   expression   resulted   in   an  
incomplete   loss   of   thymic  MOG-­reactive   Treg   cells   compared   to   controls.   It  
will   be   important   to   assess   whether   these   different   pathways   of   Treg   cell  
development  give  rise  to  functionally  distinct  subsets.  Our  observation  that  in  
retrogenic   mice   the   frequencies   of   cells   expressing   Helios   vary   in   these  
distinct  conditions  suggests  that  these  various  Treg  cells  are  not  identical.    
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The  capacity  of  antigen(s)  other  than  MOG  to  drive  thymic  selection  of  
Tconv  cells  more  efficiently  than  Treg  cells  suggests  that  these  cells  express  
TCRs  with  different  antigen-­recognition  properties.  Our  data  obtained  using  a  
panel   of   altered   peptides   support   the   notion   that   the   TCRs   from   Treg   and  
Tconv   cells   differentially   interact   with   MOG.   Some   altered   peptide   ligands  
increased   the   amounts   of   IL-­2   produced   by   the   cell   lines   expressing   Tconv  
cell-­derived  TCR  by  2.7   to  10.1-­fold   compared   to   the  original   peptide,  while  
the  maximum  increases  observed  for  the  Treg  cell-­derived  TCRs  were  lower  
(increases   of   only   0.5   to   1.6-­fold).   This   suggests   that   wild-­type  MOG   is   an  
optimal   agonist   for   MOG-­reactive   Treg   but   not   for   Tconv   cells.   This   might  
explain  why  MOG  is  so  important  for  the  development  of  MOG-­reactive  Treg  
cells.  Structural  investigations  will  be  necessary  to  precise  how  the  TCRs  from  
Treg  and  Tconv  cells  recognize  MOG.  Structural  characterization  of  two  TCRs  
carried  by  induced  human  regulatory  T  cells  recently  indicate  that  these  TCRs  
interact   differently   with   their   antigen-­MHC   complex   compared   to   previously  
characterized   TCR-­peptide-­MHC   complexes   structures   for   Tconv   cell   TCRs  
(Beringer  et  al.,  2015).    
  
Indirect  evidence  suggested   that  Treg  cell  development  was   favoured  
by  TCR  interactions  of  high  functional  avidity   for   the  selecting  antigens.  This  
notion   is   however   complicated   to   evaluate   because   antigen   sensitivity   is  
influenced   by   numerous   parameters   beyond   the   TCR   identity,   as   shown   by  
the  fact  that  individual  T  cell  clones  can  generate  progeny  with  both  high  and  
low   antigen   sensitivity   (Kroger   and   Alexander-­Miller,   2007).   Here,   the  
identification   of   MOG   as   the   cue   controlling   the   differentiation   of   MOG-­
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reactive   Treg   cells   enabled   us   to   compare   the   characteristics   distinguishing  
the  TCR  implicated  in  the  commitment  of  T  cell  progenitors  into  either  Treg  or  
Tconv   cells.  Our   data   confirmed   that   a  major   difference   between   these   two  
types   of   TCRs   was   their   functional   avidity   for   MOG,   which   was   markedly  
higher   for  Treg  cells.  Of  note,  we  have  compared  here   the  properties  of   the  
TCRs   expressed   by   Treg   and   Tconv   cells   in   a   similar   context:   we   isolated  
these  TCRs  and   then   re-­expressed   them   in   the  same   reporter  cell   line.  The  
difference   between   our   approach   and   the   methodology   used   by   others  
possibly  explains  our  different  findings  (Hood  et  al.,  2015).  
  
The  expression  by  Treg  and  Tconv  cells  of  TCRs  of  different  functional  
avidity   for   MOG   led   us   to   examine   the   relevance   of   this   dichotomy   for   the  
function   of   these   cells   in   the   periphery.   Polyclonal   Treg   cells   engineered   to  
express  a  MOG-­reactive  Treg  cell  TCR  almost  completely  prevented  disease  
induction,  while  Treg  cells  carrying  Tconv  cell  TCRs  had  only  moderate  to  no  
protective   value   in  EAE.  Based  on   these  observations,  we  propose   that   the  
expression   of   high   performance   TCRs   by   Treg   cells   is   important   for   these  
cells   to   have   a   dominant   effect   over   Tconv   cells   for   suppressing   anti-­self  
immunity.    
  
   There   is  currently   intense   interest   in   the  possibility  of  using  Treg  cells  
for   the   suppression   of   unwanted   immunity   in   adoptive   cell   therapy.   Several  
clinical  trials  have  already  been  initiated  to  examine  the  safety  and  therapeutic  
value  of  polyclonal  Treg  cells   in   the  clinic   (Brunstein  et  al.,  2011;;  Di   Ianni  et  
al.,  2011;;  Marek-­Trzonkowska  et  al.,  2012;;  Theil  et  al.,  2015).  Data  obtained  
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in   pre-­clinical   models   demonstrated   that   in   autoimmune   diseases,  
autoantigen-­reactive   Treg   cells   were   markedly   superior   to   polyclonal   Treg  
cells   to  suppress  pathology  (Stephens  et  al.,  2009).  Thus,  an  attractive  Treg  
cell-­based   strategy   for   treating   autoimmune   diseases   would   be   to   isolate   a  
patient’s   own   Treg   cells   reacting   against   a   disease-­relevant   autoantigen,  
expand   them   ex   vivo,   and   subsequently   use   these   cells   in   autologous  
adoptive  cell   therapy.  However,  autoantigen-­specific  Treg  cells  are   rare  and  
remain  difficult   to   isolate  making  their  application   in  adoptive  cellular   therapy  
challenging.   The   possibility   of   engineering   Treg   cells   by   TCR   gene   transfer  
represents  a  major  advance  on  this  point,  yet  raises  the  new  question  about  
the  choice  of  the  type  of  TCR  that  should  be  used.  Our  data  demonstrate  that  
TCRs   from   Treg   cells   are   clearly   a   preferable   choice   since   they   confer  
markedly   superior   protective   functions   to   engineered   Treg   cells   than   TCRs  
from  Tconv  cells.    
  
In   conclusion,   we   have   demonstrated   an   unexpected   role   for  
endogenous   MOG   expression   as   a   major   cue   for   the   selection   of   thymus-­
derived  MOG-­reactive  Treg  cells,  providing  the  first   identification  of  a  natural  
antigen   that   controls   Treg   cell   differentiation.   Although   we   analysed  
specifically  Treg  cells  that  express  the  public  TCRβ  chain  of  the  MOG-­reactive  
CD4+   T   cell   response   during   EAE,   which   we   selected   because   such   TCR  
usually  play  prominent  roles  during  immune  responses  (van  den  Elzen  et  al.,  
2004),   we   anticipate   that   our   findings   are   also   relevant   for   private   TCRs.  
These  results  might  help  to  understand  how  thymus-­derived  Treg  cells  have  a  
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key   role   in   preventing   autoimmune-­mediated   attack   of   self-­tissues,   while  
allowing  efficient  defence  against  infections.    
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EXPERIMENTAL  PROCEDURES    




Mouse   strains   are   described   in   Supplemental   Experimental   Procedures.  
Experiments  were  performed   in  accordance  with  German,  French,  and  U.K.  
authorities.    
  
EAE  induction  through  immunization  and  adoptive  transfer  
EAE  was  induced  and  assessed  as  described  (Fillatreau  et  al.,  2002).  Some  
mice  received  200  µg  anti-­CD25  (PC61)  intravenously  three  days  before  EAE  
induction   (Figure   1H).   The   protocol   was   in   cases   adjusted   to   use   5   µg   of  
MOG(35-­55)  or  49(H_A)  peptides  (Figure  2D).    
For   induction   of   passive   EAE   with   in   vitro-­primed   T   cells,   splenic   and   LN  
lymphocytes  of  naïve  Kaa  or  C57BL/6  mice  were  depleted  of  CD25+  cells  by  
separation  on  autoMACS  (Miltenyi  Biotech)  and  stimulated   in  vitro  for  3  days  
with  10  µg/ml  MOG(35-­55)  peptide,  recombinant  mouse  IL-­2  (10  U/ml),  IL-­12  
and  IL-­18  (each  at  25  ng/ml).  10x106   in  vitro-­primed  cells  were   then   injected  
into   naïve   C57BL/6   mice   intravenously   to   induce   EAE.   These   mice  
additionally   received   240   ng   Pertussis   toxin   intravenously   on   days   0   and   2  
after  cell  transfer.      
For   induction   of   passive  EAE  with   in   vivo-­primed  Kaa   cells,  Kaa  mice  were  
immunized  with  MOG(35-­55),  as  previously  described  (Fillatreau  et  al.,  2002).  
Draining   LN   were   harvested   8   days   after   immunization,   and   cells   were   re-­
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stimulated  in  vitro  for  3  days  with  10  µg/ml  MOG(35-­55)  peptide,  recombinant  
mouse   IL-­2   (10  U/ml),   IL-­12  and   IL-­18   (each  at   25  ng/ml).   6x106   cells  were  
then   injected   into   naïve  C57BL/6  mice   intravenously   to   induce   EAE.   These  
mice  additionally  received  240  ng  Pertussis  toxin  intravenously  on  days  0  and  
2  after  cell  transfer.      
  
For   production   of   transduced   MOG-­reactive   Tconv   cells   by   TCR   gene  
transfer,  LN  and  spleen  were  collected  from  naïve  C57BL/6  mice,  subjected  to  
a  mouse  CD4+  T  cell  pre-­enrichment  EasySep  kit  (STEMCELL  technologies),  
and  CD25+  cells  were  subsequently  eliminated  using  a  mouse  CD25  positive  
selection   EasySep   kit   (STEMCELL   technologies).   The   obtained   cells   were  
then  activated  with  anti-­CD3  (1  µg/ml),  anti-­CD28  (0.1  µg/ml),   IL-­2  (40U/ml),  
IL-­12  (25  ng/ml),  and  IL-­18  (25  ng/ml),  and  transduced  at  48  h  and  72  h  with  
MP71  retroviral  particles,  and  used   in  vitro  or  in  adoptive  transfer  at  96  h  (1-­
2x106   cells/mouse).   Recipient   mice   additionally   received   240   ng   Pertussis  
toxin  intravenously  on  days  0  and  2  after  cell  transfer.    
  
Identification  and  cloning  of  Kaa  TCRα  chains  
Kaa.Foxp3.IRES.eGFP+Tcra+/-­Tcrb+/-­  mice  were  immunized  with  MOG(35-­55)  
to  induce  EAE,  and  CD4+GFP+  as  well  as  CD4+GFP-­  cells  were  isolated  from  
their   CNS   (brain   and   spinal   cord)   using   a   combination   of   magnetic   and  
cytometric  procedures.  RNA  was  isolated  from  these  cells  using  RNeasy  mini  
Kit   (Qiagen).   cDNA   was   generated   using   a   SMARTer   5’   RACE   cDNA  
Amplification   Kit,   and   an   Advantage   2   PCR   Kit   (both   Clontech),   using   the  
primer   5’-­ACT  GGA  CCA  CAG  CCT  CAG  CGT  CA-­3’.   PCR   products   were  
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cloned   into   the   pcDNA3.1/V5-­His-­TOPO   vector   (Life   technologies).   After  
transformation  into  E.  coli  positive  colonies  were  sequenced  (GATC  Biotech).  
TCRα   sequences   were   identified   by   IMGT   HighV-­quest   software  
(www.imgt.org/HighV-­QUEST)  (Alamyar  et  al.,  2012).    
  
Expression  of  TCR  in  T.54ζ17  cells  
T.54ζ17  cells   (gift   of  B.  Malissen,  France)   (Letourneur  and  Malissen,  1989),  
which  express  mouse  CD4,  were  modified   to   stably   express   the  Kaa  TCRβ  
chain   cloned   into   a   pMig   retroviral   vector   (Van   Parijs   et   al.,   1999).   TCRα  
chains  were   cloned   into   the   pMY-­IRES-­GFP   retroviral   vector   (Cell   Biolabs).  
T.54ζ17   cells   expressing   the   Kaa   TCRβ   chain   were   transduced   with   pMY-­
IRES-­GFP   encoding   the   TCRα,   and   GFP+Vβ8.2+   cells   were   sorted   on   a  
FACSAria   II   several   times   until   cultures   stably   containing   >95%   TCR-­
expressing   cells   were   obtained.   For   each   TCRα   chain   two   TCR-­expressing  
cell  lines  were  independently  generated.  
  
Expression  of  TCR  in  HSC,  Tconv  cells,  and  Treg  cells  
The  TCRα  and  Kaa  TCRβ  sequences  were  linked  via  a  2A  element  of  porcine  
teschovirus   (p2a)   by   PCR   and   cloned   into   the   MP71   vector   (Engels   et   al.,  
2003)   via  NotI   and  EcoRI   restriction   sites   to   obtain  MP71-­TCRβ-­p2a-­TCRα.  
The  Thy1.1  gene  was  additionally  linked  to  the  TCR  chains  using  a  2A  linker  
element   of   Thosea   asigna   virus   (t2a)   to   yield   MP71-­TCRβ-­p2a-­TCRα-­t2a-­
Thy1.1.  To  simultaneously  express  miRNAs  in  the  MP71  vector,  Ctla4-­specific  
miRNA  target  sites  GGT  TCC  AAA  GGT  TGT  AGT  GTT  and  AAC  TGA  AAG  
GCC   GTT   TAT   GAA   were   predicted   by   BLOCK-­iT™   RNAi   Designer  
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(rnaidesigner.lifetechnologies.com/rnaiexpress)   and   the   respective   antisense  
sequences   were   integrated   into   two   different   miRNA   environments   (murine  
miR-­155  (Chung  et  al.,  2006)  and  an  artificial  miRNA  (Saetrom  et  al.,  2006)).  
Then,  the  miRNAs  were  inserted  into  the  MP71  intron  (Bunse  et  al.,  2014).    
  
Retroviral  transduction  
Viral  particles  for  transduction  of  HSC  and  primary  Treg  and  Tconv  cells  were  
produced   using   Plat-­E   cells   through   transient   transfection   with   the   MP71  
retrovirus  vector  using  CaPO4  precipitation.  Supernatants  containing  retroviral  
particles  were  harvested  at  48  h  and  72  h  after  transfection,  and  subsequently  
used  for  transduction  of  HSC,  Tconv,  or  Treg  cells.      
  
CD4+CD25+  Treg  and  CD4+CD25-­  Tconv  cells  were  isolated  from  spleen  and  
LN  of  naïve  C57BL/6  mice  and  stimulated  in  non-­tissue  culture  plates  coated  
with   1   µg/ml   anti-­CD3   and   anti-­CD28   (Biolegend).   Cells   were   cultured   with  
750  or  40  U/ml  recombinant  human  IL-­2  (Chiron,  Germany),  respectively,  and  
transduced   on   day   2   and   3   after   isolation   by   spinoculation   in   plates   coated  
with   RetroNektin   (TaKaRa   Biomedicals,   Japan).   Four   to   six   days   after  
isolation  cells  were  used  for  adoptive  transfer.  
  
Retroviral  supernatant  for  T.54ζ17  cells  was  produced  with  HEK-­293T  cells  by  
transient  CaPO4  transfection  with  pCgp  (Soneoka  et  al.,  1995),  MLV-­eco,  and  
pMY-­TCRα-­IRES-­eGFP  or  pMig-­Kaa-­TCRβ-­Tomato,   respectively.  Cells  were  
sequentially   transduced   to   express   TCRβ   and   TCRα   and   Tomato+eGFP+  
were  subsequently  sorted.  
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TCR-­retrogenic  mice  were  prepared  as  described  (Kieback  et  al.,  2014).    
  
Statistical  analyses  
Cumulative   disease   scores   and   data   from   peptide   stimulations   and   TCR  
retrogenic  mice  were  analyzed  with  an  unpaired  or  paired  two-­tailed  Student's  
t   test.  EAE  disease  courses  were  compared  by   repeated-­measures   two-­way  
ANOVA.  Statistical  analysis  was  performed  with  GraphPad  Prism  (GraphPad  
Software  Inc.).  *P<0.05;;  **P<0.01;;  ***P<  0.001.  
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FIGURE  LEGENDS    
Figure  1.  The  Kaa  mouse  
A.  LN  cells  isolated  from  Kaa  mice  on  day  8  post-­immunization  with  MOG(35-­
55)  were  re-­stimulated  with  MOG(35-­55)  for  3  days,  and  (left  panel)  analysed  
by   flow   cytometry   to   quantify   cytokine-­expressing   CD4+   T   cells,   or   (right  
panel)  adoptively  transferred  in  recipient  mice.  Data  show  mean  EAE  score  ±  
sem   from   a   pool   of   two   experiments   (n=12).  B.   Cells   from   LN   and   spleens  
from   naïve   Kaa   or   C57BL/6   mice   were   depleted   from   CD25+   cells,   and  
stimulated   with   MOG(35-­55)   for   3   days   in   vitro,   prior   to   analysis   by   flow  
cytometry  (left,  only  Kaa)  or  adoptive  transfer  (right).  Pooled  data  (mean  EAE  
score   ±   sem)   from   three   experiments   (C57BL/6:   n=10,  Kaa:   n=13).  C.   EAE  
was   induced   in   Kaa   (n=12)   and   C57BL/6   (n=6)   mice   by   immunization   with  
MOG(35-­55).   Data   show   mean   EAE   score   +   sem.   D.   LN   cells   of  
Kaa.Foxp3.eGFP   (Kaa,   n=4)   or   Foxp3.eGFP   (B6,   n=2)   mice   were   stained  
with  MOG-­I-­Ab-­PE   and   control-­I-­Ab-­APC   tetramers.   Data   show   frequency   of  
MOG-­I-­Ab-­binding   cells   in  Treg  and  Tconv   cells   (left,   pooled   results   from  all  
mice)   and   representative   stainings   (right)   gated   on   CD4+GFP+   cells   for  
Kaa.Foxp3.eGFP  (Kaa  Treg  cells)  and  Foxp3.eGFP  (B6  Treg  cells)  mice.  E.  
Splenocytes   from  naïve  Kaa  mice  were  depleted  or  not  of  CD25-­expressing  
cells,  and  stimulated  for  72  h  with  MOG(35-­55)  to  measure  their  proliferation  
by   3H-­thymidine   incorporation.   Data   show   mean   values   of   triplicates.  
Representative   results   from   one   of   two   experiments.   F.   EAE   course   of  
C57BL/6   mice   that   received   Treg   cells   from   naïve   Kaa   (n=12)   or   C57BL/6  
(n=13)  mice  or  PBS  (n=13)  on  day  1  before  EAE   induction  by   immunization  
with  MOG(35-­55).  Data  show   results   (mean  EAE  score  +  sem)  pooled   from  
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three  experiments.  Statistic  was  calculated  comparing  B6  Treg  vs.  Kaa  Treg  
cells.   G.   Treg   cells   from   Kaa   or   C57BL/6   mice   were   labelled   with   Cell  
Proliferation   Dye   eFluor450   and   injected   into   CD45.1+   C57BL/6  mice.   Mice  
were  immunized  with  either  MOG(35-­55)  or  OVA(323-­369)  and  the  number  of  
CD45.2+CD4+Foxp3+  cells   in   the  draining  LN  was  determined  six  days   later.  
Data  pooled  from  two  experiments  (n=9  per  group).  H.  Kaa  mice  were  treated  
with   anti-­CD25   (PC61)   (n=11)   or   left   untreated   (n=10)   and   immunized   with  
MOG(35-­55)   to   induce   EAE.   Data   show   results   (mean   EAE   score   +   sem)  
pooled  from  two  experiments.  See  also  Figure  S1.  
  
Figure  2.  Antigen  recognition  properties  of  TCR  from  MOG-­reactive  Treg  
and  Tconv  cells  
A.   Relative   frequencies   of   the   selected   TCRα   among   the   total   number   of  
sequences  analysed   for  Treg   (grey)   and  Tconv   (white)   cells.  Each   segment  
within   a   bar   corresponds   to   one   of   the   three   independent   experiments.  
Relative  frequencies  were  calculated  by  dividing  the  counts  of  each  selected  
sequence  per  experiment  by   the  total  number  of  sequences  analysed   in   this  
experiment.   The   indexes   “T”   and   “N”   indicate   sequences   found   in   the   three  
Treg   and   Tconv   cells   samplings,   respectively.   B.   The   T.54ζ17   cell   lines  
expressing  MOG-­reactive  TCRs  from  Treg  (n=17)  or  Tconv  (n=11)  cells  were  
stimulated  with  MOG(35-­55)   in   indicated  concentrations,  and   IL-­2  production  
was  quantified  by  ELISA.  Data  show  one  representative  of  three  experiments.  
C.   The   cell   lines   used   in   B   (Treg   cells:   n=17,   Tconv   cells:   n=11)   were  
stimulated  with  MOG(35-­55)  peptide  variants  or  WT  MOG(35-­55).  Data  show  
the   change   in   IL-­2   produced   after   stimulation   with   each   variant   peptide  
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relatively  to  WT  MOG(35-­55).  One  representative  of  two  experiments.  D.  Kaa  
mice  were   immunized  with   49(H_A)   or  MOG(35-­55).  Data   show  mean  EAE  
score   +   sem,   and   are   pooled   from   two   experiments   (n=12).   E.   Blood   was  
collected   from   mice   shown   in   D   on   day   10   after   immunization,   and   re-­
stimulated  for  5  h  with  MOG(35-­55)  ex  vivo  to  quantify  CD40L-­  and  cytokine-­
expressing  CD4+  T   cells.  Shown  are  mean  +   sem.  See  also  Figure  S2  and  
Table  S1.  
  
Figure  3.  Role  of  TCR  for  Treg  cell  development  
HSC  from  CD45.2+Rag1-­/-­  mice  were  transduced  with  one  of  12  MOG-­reactive  
TCR   and   used   to   reconstitute   CD45.1+   C57BL/6   mice.   A.   Donor-­derived  
CD45.2+CD4+   T   cells   were   quantified   in   blood.  B.   Blood   lymphocytes   were  
analysed   for   the   percentage   of   Foxp3+   cells   among   donor-­derived  
CD45.2+CD4+  cells.  C57BL/6  mice  were   included  as  control.  C.  Thymus  and  
spleen   of   retrogenic   mice   were   analysed   for   percentages   of   Foxp3+   cells  
among  donor-­derived  CD45.2+CD4+CD8-­  T  cells  (upper  panels)  and  absolute  
numbers   (lower   panels)   of   CD45.2+CD4+CD8-­Foxp3+   cells   9   weeks   after  
reconstitution.   D.   Expression   of   Helios   in   donor-­derived   CD45.2+CD4+CD8-­
Foxp3+  Treg  cells  in  thymus  and  spleen.  A.-­D.  Data  (mean  +  sem)  show  pool  
from  two  experiments  (n=9/10  mice  per  TCR)  and  are  analysed  comparing  all  
mice  prepared  with  Tconv  cell  TCRs  vs.  all  mice  made  with  Treg  cell  TCRs  
(unpaired  t-­test).  See  also  Figure  S3.  
  
Figure  4.  Role  of  MOG  for  the  development  of  MOG-­reactive  Treg  cells.  
A.-­C.  HSC  of  CD45.1+Rag1-­/-­  mice  were   transduced  with   one   of   four  MOG-­
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reactive  TCR  from  Treg  cells,  and  used  to  reconstitute  C57BL/6  (black  bars)  
or  Mog-­/-­   (white  bars)  mice.  Nine  weeks   later,   thymus,  spleen,  and  LN  were  
analysed.   WT   C57BL/6   (grey   bars)   were   included   as   control.   A.   and   B.  
Percentage   of   Foxp3+   cells   among   donor-­derived   CD45.1+CD4+   cells,   and  
absolute  numbers  of  CD45.1+CD4+Foxp3+  Treg  cells.  C.  Frequency  of  Helios-­
expressing   cells   in  CD45.1+CD4+Foxp3+   Treg   cells.  A.-­C.   Data   pooled   from  
two  experiments  (n=9/10  mice  per  TCR).  D.  and  E.  C57BL/6  (black  bars,  n=8)  
and   Mog-­/-­   (white   bars,   n=7)   mice   were   reconstituted   with   CD90-­depleted  
bone  marrow  cells  from  Kaa.Foxp3.eGFP  mice.  Thymocytes  were  analysed  5  
weeks   later   by   flow   cytometry   after   staining   with   MOG-­I-­Ab   tetramer   and  
αCD4.   Data   show   percentage   of   MOG-­I-­Ab-­binding   cells   among   CD4+CD8-­
GFP+  Treg  cells,  and  absolute  numbers  of  MOG-­I-­Ab-­binding  CD4+CD8-­GFP+  
Treg  cells.  Representative  stainings  show  MOG-­I-­Ab  and  control-­I-­Ab  tetramer  
staining   gated   on   live   thymic   donor-­derived   CD4+CD8-­GFP+   Treg   cells   in  
C57BL/6  and  Mog-­/-­   recipients.  E.  Absolute  numbers  of  MOG-­I-­Ab+CD4+CD8-­
GFP-­  T  cells  in  thymus  of  reconstituted  C57BL/6  and  Mog-­/-­  mice  analysed  in  
D.  Data  show  mean  +  sem,  and  are  pooled  from  two  experiments.  See  also  
Figure  S4.  
  
Figure   5.   TCR   functional   avidity   determines   the   function   of   MOG-­
reactive  Treg  and  Tconv  cells  
A.   Polyclonal   Tconv   cells   were   activated   and   transduced   with   retroviral  
vectors  encoding  for  one  of  four  MOG-­reactive  TCRs  and  the  marker  Thy1.1.  
Flow   cytometry   plots   show   expression   of   Thy1.1   by   T   cells   two   days   after  
transduction.  Numbers   indicate   the  percentage  of  Thy1.1+CD4+  cells  among  
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lymphocytes   in   the   culture.  B.   TCR-­modified   Tconv   cells   obtained   as   in   A  
were   stimulated   for   24   h   with   MOG(35-­55)   in   the   presence   of   irradiated  
splenocytes.   IFN-­γ   concentration   in   supernatant   was   measured   by   ELISA.  
Data   show   means   +   sem   of   duplicates.   One   representative   of   two  
experiments.  Statistics  were  calculated  comparing  all  values   from  Tconv  cell  
TCR   vs.   all   values   from   Treg   cell   TCRs   for   each   peptide   concentration.  C.  
and  D.  TCR-­modified  Tconv  cells  obtained  as  in  A  were  used  to  induce  EAE  
in  recipient  C57BL/6  mice  via  adoptive  transfer.  C.  Seven  days  after  transfer  
the   percentage   of   Thy1.1+   cells   among   peripheral   blood   CD4+   T   cells   was  
determined.  D.  Data  show  mean  EAE  score  +  sem.  Data   in   (C)  and  (D)  are  
pooled   from   two   experiments   (n=10   per   group).   Statistics   were   calculated  
comparing  the  EAE  curves  from  all  mice  receiving  Tconv  cell  TCRs  vs.  those  
from  mice   receiving  Treg   cell   TCRs.  E.   Polyclonal   Treg   cells   from  C57BL/6  
mice  were  activated  and  transduced  with  retroviral  vectors  encoding  for  one  of  
the  four  different  MOG-­reactive  TCRs  and  Thy1.1.  Flow  cytometry  plots  show  
expression   of   Foxp3   and   Thy1.1   by   CD4+   T   cells   on   day   two   after  
transduction.  Numbers  indicate  the  percentage  of  Thy1.1+Foxp3+  cells  among  
CD4+  T  cells.  F.  TCR-­engineered  Treg  cells  produced  as  in  E,  or  PBS,  were  
administered  to  C57BL/6  mice  one  day  before  EAE  induction  by  immunization  
with  MOG(35-­55).  Data  show  mean  EAE  score  +  sem,  and  are  pooled   from  
three  experiments  (n=9  to  15  per  group).  Statistics  were  calculated  comparing  
the  EAE  curves  from  all  mice  receiving  Tconv  cell  TCRs  vs.  those  from  mice  
receiving  Treg  cell  TCRs.  G.  Blood  samples  of  mice  from  F  were  collected  on  
day   10   after   immunization,   re-­stimulated   with   MOG(35-­55)   for   5   h,   and  
analysed   by   flow   cytometry   to   quantify   the   frequency   of   CD4+   T   cells  
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expressing   CD40L,   IFN-­γ,   or   IL-­17A.   Graphs   show   mean   ±   sem,   and   are  
pooled  from  two  experiments  (n=5  to  10  per  group).  See  also  Figure  S5.  
  
Figure  6.  Protective  function  of  engineered  MOG-­reactive  Treg  cells  
A.   and   B.   C57BL/6   mice   were   treated   with   PBS,   or   engineered   Treg   cells  
expressing   the   TCR   T6-­106   and   Thy1.1,   or   a   mock   vector   coding   only   for  
Thy1.1,   and   immunized   with   MOG(35-­55)   one   day   post-­transfer   to   induce  
EAE.  A.  On  day  9  post-­immunization,  draining  LN  (popliteal  and  inguinal)  cells  
from  5  mice  were  pooled  and  re-­stimulated   in  vitro   for  6  h  with  MOG(35-­55),  
and   analysed   for   intracellular   cytokines   and   CD40L   expression   by   flow  
cytometry.  One  representative  of  two  experiments.  B.  CNS  (brain  plus  spinal  
cord)   from   5   mice   were   pooled   and   analysed   at   indicated   days   after   EAE  
induction   by   flow   cytometry.   One   representative   of   two   experiments.   C.  
C57BL/6   mice   were   immunized   with   MOG(35-­55)   and   treated   8   days   later  
with  2x106  T6-­106  TCR-­transduced  Treg  cells  or  PBS.  Data  show  mean  EAE  
score  +  sem,  and  cumulative  disease  scores  (pooled  from  three  experiments  
with   n=14/15   per   group).   D.   C57BL/6   mice   received   2x106   T6-­106   TCR-­
transduced   Treg   cells   or   PBS,   and   were   immunized   6   weeks   later   with  
MOG(35-­55)   to   induce   EAE.   Data   show   mean   EAE   score   +   sem,   and  
cumulative   disease   scores   (pool   from   two   experiments   with   n=10/14   per  
group).  See  also  Figure  S6.  
  
Figure  7.  CTLA-­4  controls  protection  from  EAE  by  engineered  Treg  cells  
A.   Design   of   the   retroviral   vector   coding   for   T6-­106   TCR,   Thy1.1,   and   two  
intronic  miRNAs.  B.  Polyclonal  Treg  cells  were  activated  and  transduced  with  
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a   vector   as   in   A   harbouring   Ctla-­4-­,   Cd49d-­   or   Tnfrsf18-­   (GITR)   specific  
miRNAs,   or   control   miRNAs,   and   analysed   two   days   post-­transduction   for  
CTLA-­4,  CD49d  or  GITR  expression,  respectively.  Plots  are  gated  on  Foxp3+  
cells.  One  representative  of  three  experiments.  C.  C57BL/6  mice  were  treated  
with  2x105  Treg  cells   transduced  as   in  B,  and   immunized  one  day   later  with  
MOG(35-­55).  Data  show  mean  EAE  score  +  sem  (pool  from  two  experiments,  
n=10  per  group).  D.  Mice  treated  with  transduced  CTLA-­4-­silenced  Treg  cells,  
and   immunised   with   MOG(35-­55)   as   in   C   were   analysed   on   day   13   post-­
immunization  by  flow  cytometry  to  measure  expressed  amounts  of  CTLA-­4  in  
the  administered   transduced  CD45.2+Thy1.1+CD4+Foxp3+  Treg  cells   (n=5)   in  
spleen.  E.  Absolute  numbers  of  administered  transduced  Thy1.1+Foxp3+  Treg  
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